,trastuzumab deruxtecan
roche,astrazeneca,daiichi sankyo
['destiny breast03', 'breast']
great presentation by on safety from destiny breast03
no g4/5 ild still with longer follow-up #asco22 
Chief, Division of Breast Oncology @DanaFarber
Tennis fan
Mother of two teenage girls